Outlook Therapeutics Reports Positive Efficacy and Safety Data from Pivotal Phase 3 NORSE TWO Trial of ONS-5010 / LYTENAVA™ (bevacizumab-vikg) for the Treatment of Wet AMD

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. ABBV
2. MU
3. SPCX
4. ACN
5. IBM
6. DPZ
7. NVDA
8. PRIM
9. META
10. SPY

Go back to Outlook Therapeutics Reports Positive Efficacy and Safety Data from Pivotal Phase 3 NORSE TWO Trial of ONS-5010 / LYTENAVA™ (bevacizumab-vikg) for the Treatment of Wet AMD

Outlook Therapeutics Incs. (OTLK) PT Raised to $6 at H.C. Wainwright

August 3, 2021 10:56 AM EDT

H.C. Wainwright analyst Douglas Tsao raised the price target on Outlook Therapeutics Incs. (NASDAQ: OTLK) to $6.00 (from $5.00) while maintaining a Buy rating.

... More

Outlook Therapeutics (OTLK) Climbs 41%

August 3, 2021 7:43 AM EDT

Outlook Therapeutics (NASDAQ: OTLK) Climbs 41%

Earlier Outlook Therapeutics (OTLK) Reports Positive Data from Pivotal Phase 3 NORSE TWO Trial of ONS-5010... More